Association of β-Amyloid and Basal Forebrain With Cortical Thickness and Cognition in Alzheimer and Lewy Body Disease Spectra.

Alzheimer Disease / complications Amyloid beta-Peptides / metabolism Basal Forebrain / metabolism Brain / metabolism Cognition Cognitive Dysfunction Cross-Sectional Studies Humans Lewy Body Disease / complications Positron-Emission Tomography

Journal

Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060

Informations de publication

Date de publication:
01 03 2022
Historique:
received: 17 06 2021
accepted: 21 12 2021
pubmed: 1 1 2022
medline: 7 4 2022
entrez: 31 12 2021
Statut: ppublish

Résumé

Cholinergic degeneration and β-amyloid contribute to brain atrophy and cognitive dysfunction in Alzheimer disease (AD) and Lewy body disease (LBD), but their relationship has not been comparatively evaluated. In this cross-sectional study, we recruited 28 normal controls (NC), 55 patients with AD mild cognitive impairment (MCI), 34 patients with AD dementia, 28 patients with LBD MCI, and 51 patients with LBD dementia. Participants underwent cognitive evaluation, brain MRI to measure the basal forebrain (BF) volume and global cortical thickness (CTh), and BF volume mediated the association between FBB-SUVR and CTh in both the AD and LBD spectra, while FBB-SUVR was associated with CTh independently of BF volume only in the LBD spectrum. Significant correlation between voxel-wise FBB-SUVR and CTh was observed only in the LBD group. FBB-SUVR was independently associated with widespread cognitive dysfunction in both the AD and LBD spectra, especially in the memory domain (standardized beta [B] for AD spectrum = -0.60, B for LBD spectrum = -0.33). In the AD spectrum, BF volume was associated with memory dysfunction (B = 0.18), and CTh was associated with language (B = 0.21) and executive (B = 0.23) dysfunction. In the LBD spectrum, however, BF volume and CTh were independently associated with widespread cognitive dysfunction. There is a common β-amyloid-related degenerative mechanism with or without the mediation of BF in the AD and LBD spectra, while the association of BF atrophy with cognitive dysfunction is more profound and there is localized β-amyloid-cortical atrophy interaction in the LBD spectrum.

Identifiants

DOI: 10.1212/WNL.0000000000013277 PMID: 34969939 PMC: PMC8901177
pubmed: 34969939
pii: WNL.0000000000013277
doi: 10.1212/WNL.0000000000013277
pmc: PMC8901177
doi:

Substances chimiques

Amyloid beta-Peptides 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e947-e957

Informations de copyright

© 2021 American Academy of Neurology.

Références

Am J Pathol. 2011 Nov;179(5):2533-50
pubmed: 21945902
Front Aging Neurosci. 2018 Jul 18;10:223
pubmed: 30072890
Dement Geriatr Cogn Disord. 2004;17 Suppl 1:3-14
pubmed: 14676464
Neuroimage. 2001 Jul;14(1 Pt 1):21-36
pubmed: 11525331
Neurobiol Aging. 2018 Dec;72:32-39
pubmed: 30205358
Brain. 2016 Oct;139(Pt 10):2740-2750
pubmed: 27452602
Sci Transl Med. 2020 Jan 1;12(524):
pubmed: 31894103
Mov Disord. 2007 Sep 15;22(12):1689-707; quiz 1837
pubmed: 17542011
J Korean Med Sci. 2010 Jul;25(7):1071-6
pubmed: 20592901
Ann Neurol. 2016 Aug;80(2):247-58
pubmed: 27323247
J Neurol. 2015 Feb;262(2):479-80
pubmed: 25504308
Neurology. 2017 Jul 4;89(1):88-100
pubmed: 28592453
Alzheimers Dement. 2015 Aug;11(8):964-74
pubmed: 25824567
Neuron. 2020 Jan 22;105(2):260-275.e6
pubmed: 31759806
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Front Aging Neurosci. 2019 Aug 20;11:211
pubmed: 31481888
J Neurol Neurosurg Psychiatry. 1988 Jun;51(6):745-52
pubmed: 2841426
Eur J Nucl Med Mol Imaging. 2008 Mar;35 Suppl 1:S25-9
pubmed: 18196237
AJR Am J Roentgenol. 1987 Aug;149(2):351-6
pubmed: 3496763
Cereb Cortex. 2010 Jul;20(7):1685-95
pubmed: 19889714
J Neural Transm (Vienna). 1999;106(5-6):525-35
pubmed: 10443555
Ann Neurol. 2020 May;87(5):739-750
pubmed: 32078179
Neurology. 2000 Jan 25;54(2):407-11
pubmed: 10668703
Alzheimers Dement. 2014 Oct;10(5 Suppl):S344-53
pubmed: 24418052
Neuroimage Clin. 2014 Nov 27;7:105-13
pubmed: 25610772
Alzheimers Dement. 2015 May;11(5):494-503.e3
pubmed: 25048578
Neuroimage. 2005 Aug 1;27(1):210-21
pubmed: 15896981
Neuroimage. 2012 Aug 15;62(2):782-90
pubmed: 21979382
Neuroimage. 2014 Nov 15;102 Pt 2:674-87
pubmed: 25175542
Biochim Biophys Acta. 2009 Jul;1792(7):730-40
pubmed: 18718530
Brain. 2007 Mar;130(Pt 3):708-19
pubmed: 17267521
Curr Neuropharmacol. 2016;14(1):101-15
pubmed: 26813123
Alzheimers Res Ther. 2016 Jul 20;8:31
pubmed: 27484179
Nat Commun. 2016 Nov 04;7:13249
pubmed: 27811848
Neuroimage. 2003 Feb;18(2):198-213
pubmed: 12595176
Lancet Neurol. 2010 Jan;9(1):119-28
pubmed: 20083042
Cereb Cortex. 2016 Jun;26(6):2411-2426
pubmed: 25840425
Brain. 2005 Nov;128(Pt 11):2626-44
pubmed: 16014654
Alzheimers Dement. 2018 Oct;14(10):1243-1252
pubmed: 29936148
Brain. 2007 Sep;130(Pt 9):2375-86
pubmed: 17698497
JAMA Neurol. 2013 Feb;70(2):241-7
pubmed: 23183921
Brain. 2018 Jan 1;141(1):165-176
pubmed: 29228203
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
J Alzheimers Dis. 2014;40(3):687-700
pubmed: 24503619
Cereb Cortex. 2009 Mar;19(3):497-510
pubmed: 18632739
Mov Disord. 2012 Mar;27(3):349-56
pubmed: 22275317
Neuron. 2009 Jul 30;63(2):178-88
pubmed: 19640477
Neurology. 2010 Mar 16;74(11):885-92
pubmed: 20181924
Nat Commun. 2018 Jan 2;9(1):12
pubmed: 29295991

Auteurs

Han Soo Yoo (HS)

From the Department of Neurology (H.S.Y., S.J., P.H.L., Y.H.S., B.S.Y.), Brain Research Institute (S.J.), Severance Biomedical Science Institute (M.J.K.), and Department of Nuclear Medicine (M.Y.), Yonsei University College of Medicine, Seoul, South Korea; Sorbonne University (E.C., H.H.), GRC N0. 21, Alzheimer Precision Medicine, AP-HP, Pitié-Salpêtrière Hospital; Qynapse (E.C.), Paris, France; German Center for Neurodegenerative Diseases (DZNE)-Rostock/Greifswald (M.J.G., S.T.), Rostock, Germany; Unidad de Trastornos del Movimiento (M.J.G.), Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Spain; Department of Psychosomatic Medicine (S.T.), University Medicine Rostock, Germany; and McGill Center for Integrative Neuroscience (A.C.E.), Montreal Neurological Institute, McGill University, Quebec, Canada.

Seun Jeon (S)

From the Department of Neurology (H.S.Y., S.J., P.H.L., Y.H.S., B.S.Y.), Brain Research Institute (S.J.), Severance Biomedical Science Institute (M.J.K.), and Department of Nuclear Medicine (M.Y.), Yonsei University College of Medicine, Seoul, South Korea; Sorbonne University (E.C., H.H.), GRC N0. 21, Alzheimer Precision Medicine, AP-HP, Pitié-Salpêtrière Hospital; Qynapse (E.C.), Paris, France; German Center for Neurodegenerative Diseases (DZNE)-Rostock/Greifswald (M.J.G., S.T.), Rostock, Germany; Unidad de Trastornos del Movimiento (M.J.G.), Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Spain; Department of Psychosomatic Medicine (S.T.), University Medicine Rostock, Germany; and McGill Center for Integrative Neuroscience (A.C.E.), Montreal Neurological Institute, McGill University, Quebec, Canada.
ORCID: 0000-0003-2817-3352

Enrica Cavedo (E)

From the Department of Neurology (H.S.Y., S.J., P.H.L., Y.H.S., B.S.Y.), Brain Research Institute (S.J.), Severance Biomedical Science Institute (M.J.K.), and Department of Nuclear Medicine (M.Y.), Yonsei University College of Medicine, Seoul, South Korea; Sorbonne University (E.C., H.H.), GRC N0. 21, Alzheimer Precision Medicine, AP-HP, Pitié-Salpêtrière Hospital; Qynapse (E.C.), Paris, France; German Center for Neurodegenerative Diseases (DZNE)-Rostock/Greifswald (M.J.G., S.T.), Rostock, Germany; Unidad de Trastornos del Movimiento (M.J.G.), Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Spain; Department of Psychosomatic Medicine (S.T.), University Medicine Rostock, Germany; and McGill Center for Integrative Neuroscience (A.C.E.), Montreal Neurological Institute, McGill University, Quebec, Canada.

MinJin Ko (M)

From the Department of Neurology (H.S.Y., S.J., P.H.L., Y.H.S., B.S.Y.), Brain Research Institute (S.J.), Severance Biomedical Science Institute (M.J.K.), and Department of Nuclear Medicine (M.Y.), Yonsei University College of Medicine, Seoul, South Korea; Sorbonne University (E.C., H.H.), GRC N0. 21, Alzheimer Precision Medicine, AP-HP, Pitié-Salpêtrière Hospital; Qynapse (E.C.), Paris, France; German Center for Neurodegenerative Diseases (DZNE)-Rostock/Greifswald (M.J.G., S.T.), Rostock, Germany; Unidad de Trastornos del Movimiento (M.J.G.), Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Spain; Department of Psychosomatic Medicine (S.T.), University Medicine Rostock, Germany; and McGill Center for Integrative Neuroscience (A.C.E.), Montreal Neurological Institute, McGill University, Quebec, Canada.

Mijin Yun (M)

From the Department of Neurology (H.S.Y., S.J., P.H.L., Y.H.S., B.S.Y.), Brain Research Institute (S.J.), Severance Biomedical Science Institute (M.J.K.), and Department of Nuclear Medicine (M.Y.), Yonsei University College of Medicine, Seoul, South Korea; Sorbonne University (E.C., H.H.), GRC N0. 21, Alzheimer Precision Medicine, AP-HP, Pitié-Salpêtrière Hospital; Qynapse (E.C.), Paris, France; German Center for Neurodegenerative Diseases (DZNE)-Rostock/Greifswald (M.J.G., S.T.), Rostock, Germany; Unidad de Trastornos del Movimiento (M.J.G.), Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Spain; Department of Psychosomatic Medicine (S.T.), University Medicine Rostock, Germany; and McGill Center for Integrative Neuroscience (A.C.E.), Montreal Neurological Institute, McGill University, Quebec, Canada.

Phil Hyu Lee (PH)

From the Department of Neurology (H.S.Y., S.J., P.H.L., Y.H.S., B.S.Y.), Brain Research Institute (S.J.), Severance Biomedical Science Institute (M.J.K.), and Department of Nuclear Medicine (M.Y.), Yonsei University College of Medicine, Seoul, South Korea; Sorbonne University (E.C., H.H.), GRC N0. 21, Alzheimer Precision Medicine, AP-HP, Pitié-Salpêtrière Hospital; Qynapse (E.C.), Paris, France; German Center for Neurodegenerative Diseases (DZNE)-Rostock/Greifswald (M.J.G., S.T.), Rostock, Germany; Unidad de Trastornos del Movimiento (M.J.G.), Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Spain; Department of Psychosomatic Medicine (S.T.), University Medicine Rostock, Germany; and McGill Center for Integrative Neuroscience (A.C.E.), Montreal Neurological Institute, McGill University, Quebec, Canada.

Young H Sohn (YH)

From the Department of Neurology (H.S.Y., S.J., P.H.L., Y.H.S., B.S.Y.), Brain Research Institute (S.J.), Severance Biomedical Science Institute (M.J.K.), and Department of Nuclear Medicine (M.Y.), Yonsei University College of Medicine, Seoul, South Korea; Sorbonne University (E.C., H.H.), GRC N0. 21, Alzheimer Precision Medicine, AP-HP, Pitié-Salpêtrière Hospital; Qynapse (E.C.), Paris, France; German Center for Neurodegenerative Diseases (DZNE)-Rostock/Greifswald (M.J.G., S.T.), Rostock, Germany; Unidad de Trastornos del Movimiento (M.J.G.), Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Spain; Department of Psychosomatic Medicine (S.T.), University Medicine Rostock, Germany; and McGill Center for Integrative Neuroscience (A.C.E.), Montreal Neurological Institute, McGill University, Quebec, Canada.

Michel J Grothe (MJ)

From the Department of Neurology (H.S.Y., S.J., P.H.L., Y.H.S., B.S.Y.), Brain Research Institute (S.J.), Severance Biomedical Science Institute (M.J.K.), and Department of Nuclear Medicine (M.Y.), Yonsei University College of Medicine, Seoul, South Korea; Sorbonne University (E.C., H.H.), GRC N0. 21, Alzheimer Precision Medicine, AP-HP, Pitié-Salpêtrière Hospital; Qynapse (E.C.), Paris, France; German Center for Neurodegenerative Diseases (DZNE)-Rostock/Greifswald (M.J.G., S.T.), Rostock, Germany; Unidad de Trastornos del Movimiento (M.J.G.), Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Spain; Department of Psychosomatic Medicine (S.T.), University Medicine Rostock, Germany; and McGill Center for Integrative Neuroscience (A.C.E.), Montreal Neurological Institute, McGill University, Quebec, Canada.

Stefan Teipel (S)

From the Department of Neurology (H.S.Y., S.J., P.H.L., Y.H.S., B.S.Y.), Brain Research Institute (S.J.), Severance Biomedical Science Institute (M.J.K.), and Department of Nuclear Medicine (M.Y.), Yonsei University College of Medicine, Seoul, South Korea; Sorbonne University (E.C., H.H.), GRC N0. 21, Alzheimer Precision Medicine, AP-HP, Pitié-Salpêtrière Hospital; Qynapse (E.C.), Paris, France; German Center for Neurodegenerative Diseases (DZNE)-Rostock/Greifswald (M.J.G., S.T.), Rostock, Germany; Unidad de Trastornos del Movimiento (M.J.G.), Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Spain; Department of Psychosomatic Medicine (S.T.), University Medicine Rostock, Germany; and McGill Center for Integrative Neuroscience (A.C.E.), Montreal Neurological Institute, McGill University, Quebec, Canada.

Harald Hampel (H)

From the Department of Neurology (H.S.Y., S.J., P.H.L., Y.H.S., B.S.Y.), Brain Research Institute (S.J.), Severance Biomedical Science Institute (M.J.K.), and Department of Nuclear Medicine (M.Y.), Yonsei University College of Medicine, Seoul, South Korea; Sorbonne University (E.C., H.H.), GRC N0. 21, Alzheimer Precision Medicine, AP-HP, Pitié-Salpêtrière Hospital; Qynapse (E.C.), Paris, France; German Center for Neurodegenerative Diseases (DZNE)-Rostock/Greifswald (M.J.G., S.T.), Rostock, Germany; Unidad de Trastornos del Movimiento (M.J.G.), Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Spain; Department of Psychosomatic Medicine (S.T.), University Medicine Rostock, Germany; and McGill Center for Integrative Neuroscience (A.C.E.), Montreal Neurological Institute, McGill University, Quebec, Canada.
ORCID: 0000-0003-0894-8982

Alan C Evans (AC)

From the Department of Neurology (H.S.Y., S.J., P.H.L., Y.H.S., B.S.Y.), Brain Research Institute (S.J.), Severance Biomedical Science Institute (M.J.K.), and Department of Nuclear Medicine (M.Y.), Yonsei University College of Medicine, Seoul, South Korea; Sorbonne University (E.C., H.H.), GRC N0. 21, Alzheimer Precision Medicine, AP-HP, Pitié-Salpêtrière Hospital; Qynapse (E.C.), Paris, France; German Center for Neurodegenerative Diseases (DZNE)-Rostock/Greifswald (M.J.G., S.T.), Rostock, Germany; Unidad de Trastornos del Movimiento (M.J.G.), Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Spain; Department of Psychosomatic Medicine (S.T.), University Medicine Rostock, Germany; and McGill Center for Integrative Neuroscience (A.C.E.), Montreal Neurological Institute, McGill University, Quebec, Canada.

Byoung Seok Ye (BS)

From the Department of Neurology (H.S.Y., S.J., P.H.L., Y.H.S., B.S.Y.), Brain Research Institute (S.J.), Severance Biomedical Science Institute (M.J.K.), and Department of Nuclear Medicine (M.Y.), Yonsei University College of Medicine, Seoul, South Korea; Sorbonne University (E.C., H.H.), GRC N0. 21, Alzheimer Precision Medicine, AP-HP, Pitié-Salpêtrière Hospital; Qynapse (E.C.), Paris, France; German Center for Neurodegenerative Diseases (DZNE)-Rostock/Greifswald (M.J.G., S.T.), Rostock, Germany; Unidad de Trastornos del Movimiento (M.J.G.), Servicio de Neurología y Neurofisiología Clínica, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Spain; Department of Psychosomatic Medicine (S.T.), University Medicine Rostock, Germany; and McGill Center for Integrative Neuroscience (A.C.E.), Montreal Neurological Institute, McGill University, Quebec, Canada. romel79@gmail.com.
ORCID: 0000-0003-0187-8440

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Maladie d'Alzheimer › Association of β-Amyloid and Basal Forebrain...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Peptides bêta-amyloïdes › Association of β-Amyloid and Basal Forebrain...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Prosencéphale › Télencéphale › Cerveau › Cortex olfactif › Prosencéphale basal › Association of β-Amyloid and Basal Forebrain...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Association of β-Amyloid and Basal Forebrain...
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Cognition › Association of β-Amyloid and Basal Forebrain...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Troubles de la cognition › Dysfonctionnement cognitif › Association of β-Amyloid and Basal Forebrain...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études transversales › Association of β-Amyloid and Basal Forebrain...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Association of β-Amyloid and Basal Forebrain...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Maladie à corps de Lewy › Association of β-Amyloid and Basal Forebrain...
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Association of β-Amyloid and Basal Forebrain...